Engitix is a biotechnology company focused on discovering and developing novel therapeutics by leveraging its proprietary extracellular matrix platform. By using human tissue-derived ECM Platform ...
GSK’s latest hepatology partnership is posing a less-asked question—how do you stop patients’ liver fibrosis from regressing?
Money Talks News on MSN
This common chemical is now linked to potentially fatal liver disease — especially for higher-income households — researchers find
A recent study reveals that a common household chemical could potentially triple your risk of serious liver scarring.
Chronic liver injury results in the development of liver fibrosis in approximately 25% of individuals in response to diverse insults, and several aspects of the development of liver injury appear to ...
New research from the University of Pittsburgh School of Pharmacy sheds light on the processes that lead to liver fibrosis and suggests a novel treatment approach for this common and serious condition ...
NEW ORLEANS, June 08, 2026--insitro, the physical AI company unlocking causal human biology, today presented new preclinical data from its metabolic dysfunction-associated steatohepatitis (MASH) ...
UK biotech Engitix, which is pioneering extracellular matrix (ECM)-driven drug discovery, today announced a strategic ...
Liver fibrosis is a feature of many hepatic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Various candidate drugs directly targeting mechanisms of fibrosis have shown ...
Researchers at UCLA Health uncovered new information about the role inflammation plays in mitigating liver fibrosis, which is associated with metabolic-associated fatty liver disease (MAFLD), one of ...
Please provide your email address to receive an email when new articles are posted on . Noninvasive tests for liver fibrosis screening performed worse among Black adults vs. other racial-ethnic groups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results